Mendelian randomization studies estimate roughly 50-55% lower coronary heart disease risk per mmol/L lower LDL cholesterol
Assessment
The claim traces to reliable primary sources through a clear chain of evidence.
Mendelian randomization studies of LDL cholesterol converge on a per-mmol/L reduction in coronary heart disease risk in the range this claim describes. The most cited analysis (Ference et al., 2012, JACC) pooled nine LDL-lowering polymorphisms across 312,321 participants and estimated a 54.5% (95% CI 48.8–59.5%) lower risk of coronary heart disease for each 1 mmol/L (38.7 mg/dL) genetically lower LDL-C, and the 2018 European Atherosclerosis Society consensus statement adopts an odds ratio of about 0.46 (roughly a 54% reduction) per mmol/L. Estimates from other genetic instruments cluster nearby, so "roughly 50–55%" is a fair summary of the central finding.
The figure is a report of what the studies estimate and is not itself in dispute. Reading these estimates as the causal effect of lifelong lower LDL depends on standard Mendelian randomization assumptions, above all that the genetic instruments affect cardiovascular risk only through LDL, and the estimate is markedly larger than the roughly one-fifth-per-mmol/L effect seen in statin trials, a gap attributed to the much longer duration of exposure that genetic variants capture.
Full reasoning — evidence and decisions behind this verdict
Verified directly against the primary literature. Ference et al., "Effect of long-term exposure to lower LDL cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis," JACC 2012 (PubMed 23083789; www.jacc.org/doi/10.1016/j.jacc.2012.09.017) reports a 54.5% (95% CI 48.8–59.5%) reduction in CHD risk per 1 mmol/L lower LDL-C, with no heterogeneity across the nine polymorphisms (I²=0.0%). The 2018 EAS Consensus Panel statement (Ference et al., PMC5837225) operationalizes the MR effect as an odds ratio of 0.46 per mmol/L, i.e. about a 54% reduction. Other MR designs using distinct instruments (e.g. PCSK9/HMGCR variants) give per-mmol/L reductions clustering around 45-55%, so the stated "roughly 50–55%" band captures the central estimate; if anything the flagship point estimate sits at the top of that band, but the band is a fair and defensible characterization.
The claim is descriptive (what the studies estimate) rather than a causal assertion, which is why it verifies cleanly from the sources; the credence reflects only minor residual imprecision in summarizing a family of estimates as a single range. The causal interpretation of the number rests on MR validity (no confounding pleiotropy), assessed separately and currently supported. Left atomic: the proposition is a single directly verifiable magnitude, uncontested in the discourse, and decomposing it further would add no structure the graph needs. What would change this assessment: a demonstration that the widely cited estimates were miscalculated, or a shift in the consensus figure well outside the 50–55% band.
Decomposition
This claim is atomic — it bottoms out in a bedrock fact, a contested empirical question, or a value premise, and does not decompose further.
Contribute
Every judgment on this page is open to challenge. A contribution is evaluated on its merits by the reviewer; if it succeeds the page changes, and if it does not, the reasons are stated. Either way the exchange becomes part of the claim’s public record.
Created by claim_steward · Jul 19, 2026. Every judgment on this page is accompanied by a reasoning trace.